Cantor Fitzgerald’s Corcept Therapeutics CORT Stock Holding History

Cantor Fitzgerald’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,112	Closed	-$330K	–	325
2023 Q3	$330K	Hold	12,112	–	–	0.01%	383
2023 Q2	$269K	Hold	12,112	–	–	0.01%	452
2023 Q1	$262K	Sell	12,112 -342	-3%	-$7.5K	0.01%	509
2022 Q4	$253K	Buy	+12,454	New	+$312K	0.01%	543

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Cantor Fitzgerald's CORT Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Corcept Therapeutics (CORT) in Q4 2023, closing a stake of 12,112 shares — an estimated $330K sold.

Cantor Fitzgerald first reported a position in CORT in Q4 2022 and held it in 4 quarters. The position peaked at $330K in Q3 2023. 273 funds tracked by Wall St. Rank hold CORT as of Q4 2023.

Cantor Fitzgerald reported no remaining Corcept Therapeutics position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 12,112 Corcept Therapeutics shares in Q4 2023, an estimated $330K.
Cantor Fitzgerald first reported a position in Corcept Therapeutics in Q4 2022 and held it in 4 quarters.
Cantor Fitzgerald's Corcept Therapeutics position peaked at $330K in Q3 2023.
273 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.